Biocon readying psoriasis drug
By ENS Economic Bureau - HYDERABAD
26th January 2013 09:37 AM
Biocon is planning to launch the skin disease drug under the brand — Alzumab — in India during the second quarter of 2013.
The drug is used in the treatment of moderate to severe psoriasis, which is estimated to have a market size of over $8 billion by 2016 globally.
The company intends to manufacture and formulate the product as an infusion drug at its biopharma manufacturing facility at Biocon Park in Bangalore.
“We expect it (Alzumab) to be a Rs 100 crore product in the next four years,” Shaw said.
The company was targeting revenue of over Rs 100 crore from its skin disease drug over the next four years.
Meanwhile, Shaw wasn’t in favour of compulsory licensing. Drugs brought under the compulsory licence perview will have a significant price difference to that of multi-national brands and is an attempt by the government to make products affordable to common man.
- India's bleeding insurgencies: Lessons from Latin America
- Western Ghat report has imperialist mindset: Ecologist
- Lot more to India-China ties than border stand-off: Experts
- Major industrial conglomerates making a beeline for Haryana
- Man kidnapped 23 years ago finds kin thanks to Google Maps
- Bangalore's techies start 'brand tattoos' craze
- Indian circuses struggle to adapt after court bans
- Want hassle-free tatkal ticket? Personally visit special counters
- Rs 8K-crore plan for upgrading ICVs of Army
- Man arrested for attempt to attack TV host Ranjini Haridas
- Kalabhavan Mani missing after assaulting forest staff
- Sreesanth, 2 other players 'confess'; more players under scanner
- Tamil Brahmi script dating to 500 BC found near Erode
- Meghalaya's CMJ University faces probe after awarding suspicious PhDs
- Shift me from ‘Anda’ cell, pleads Sanjay Dutt
- The toxic truth about ripe mangoes